Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit

Tumors may evade immune-based treatment through mechanisms that are not captured by standard mutation-focused analyses. New findings demonstrate that RNA splicing changes in lung tumors may help explain differences in immunotherapy response.

The Jackson Laboratory (Bar Harbor, Maine) led research identifying altered STAT2 RNA splicing as a mechanism associated with lung tumor response to immunotherapy. The study found that tumors can disable STAT2 without mutations by changing how RNA instructions are processed. Using long-read RNA sequencing, the team discovered thousands of previously unrecognized RNA variants in lung tumors.

The work focused on alternative RNA splicing, a process that produces different RNA isoforms from the same gene. In STAT2, an isoform retaining an extra segment called an intron was found in patients who responded to anti-programmed death ligand 1 (anti-PD-L1) therapy. An isoform lacking that intron was found in nonresponders, suggesting that these splicing signatures may help identify patients more likely to benefit before treatment begins.

The researchers analyzed two large clinical trials of the immunotherapy drug atezolizumab. Specific STAT2 RNA splicing patterns were associated with longer survival after immunotherapy. The article notes that most reference databases used in cancer research and testing do not include these newly discovered splicing patterns.

The study was published in Science on October 22, 2026 under the title “Intron retention regulates STAT2 function and associates with immunotherapy response in lung cancer.” Institutions named in the article include The Jackson Laboratory for Genomic Medicine, the NCI-designated Jackson Laboratory Cancer Center, and UConn Health. The researchers have filed a provisional patent application covering correction of the splicing mistake with RNA-based drugs and prediction of immunotherapy response.

Related Links
The Jackson Laboratory